Skip Navigation

European Heart Journal 2002 23(18):1412-1414; doi:10.1053/euhj.2002.3252
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Raatikainen, M.J.P.
Right arrow Articles by Huikuri, H.V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raatikainen, M.J.P.
Right arrow Articles by Huikuri, H.V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Management of atrial fibrillation in patients with implantable cardioverter defibrillator. Do all need a dual chamber device?

M.J.P. Raatikainen and H.V. Huikuri

University of Oulu, Department of Internal Medicine, Division of Cardiology, Oulu, Finland

References

  1. Hauer RN, Aliot E, Block M. Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. Eur Heart J. 2001;22:1074–1081[Free Full Text]
  2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482[Free Full Text]
  3. Best PJ, Hayes DL, Stanton MS. The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators. PACE. 1999;22:79–85
  4. Gronefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol. 2000;11:1208–1214[CrossRef][ISI][Medline]
  5. Wyse DG, Love JC, Yao Q. Atrial fibrillation: a risk factor for increased mortality—an AVID registry analysis. J Interv Card Electrophysiol. 2001;5:267–273[CrossRef][ISI][Medline]
  6. Ricci R, Pignalberi C, Disertori M. Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias. Eur Heart J. 2002;23:1471–1479[Abstract/Free Full Text]
  7. Swerdlow CD, Schoels W, Dijkman B. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter-defibrillator. For the Worldwide Jewel AF Investigators. Circulation. 2000;101:878–885[Abstract/Free Full Text]
  8. Gold MR, Sulke N, Schwartzman DS, Mehra R, Euler DE. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001;12:1247–1253[CrossRef][ISI][Medline]
  9. Schoels W, Swerdlow CD, Jung W, Stein KM, Seidl K, Haffajee CJ. Worldwide clinical experience with a new dual-chamber implantable cardioverter defibrillator system. J Cardiovasc Electrophysiol. 2001;12:521–528[CrossRef][ISI][Medline]
  10. Dijkman B, Wellens HJ. Dual chamber arrhythmia detection in the implantable cardioverter defibrillator. J Cardiovasc Electrophysiol. 2000;11:1105–1115[ISI][Medline]
  11. Friedman PA, Dijkman B, Warman EN. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation. 2001;104:1023–1028[Abstract/Free Full Text]
  12. Israel CW, Gronefeld G, Ehrlich JR, Hohnloser SH. Suppression of atrial tachyarrhythmias by pacing. J Cardiovasc Electrophysiol. 2002;13:S31–S39[ISI][Medline]
  13. Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?). Circulation. 2001;104:1564–1570[Free Full Text]
  14. Cleland JG, Alamgir F, Nikitin NP, Clark AL, Norell M. What is the optimal medical management of ischemic heart failure? Prog Cardiovasc Dis. 2001;43:433–455[CrossRef][ISI][Medline]
  15. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608–2614[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Raatikainen, M.J.P.
Right arrow Articles by Huikuri, H.V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raatikainen, M.J.P.
Right arrow Articles by Huikuri, H.V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?